1.87
0.00%
0.00
전일 마감가:
$1.87
열려 있는:
$1.91
하루 거래량:
4.64M
Relative Volume:
4.03
시가총액:
$91.40M
수익:
-
순이익/손실:
$-67.68M
주가수익비율:
-1.0809
EPS:
-1.73
순현금흐름:
$-54.24M
1주 성능:
-38.28%
1개월 성능:
-56.41%
6개월 성능:
-84.17%
1년 성능:
-89.86%
Cabaletta Bio Inc Stock (CABA) Company Profile
명칭
Cabaletta Bio Inc
전화
(267) 759-3100
주소
2929 ARCH STREET, PHILADELPHIA, PA
CABA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
CABA | 1.87 | 91.40M | 0 | -67.68M | -54.24M | -1.73 |
VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-09-05 | 개시 | Citigroup | Buy |
2023-07-18 | 개시 | Guggenheim | Buy |
2023-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2022-08-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2021-12-08 | 개시 | Wells Fargo | Overweight |
2021-10-19 | 재개 | Morgan Stanley | Overweight |
2021-06-30 | 개시 | Mizuho | Buy |
2021-01-08 | 개시 | Chardan Capital Markets | Buy |
2020-10-13 | 개시 | H.C. Wainwright | Buy |
2019-11-19 | 개시 | Cowen | Outperform |
2019-11-19 | 개시 | Evercore ISI | Outperform |
2019-11-19 | 개시 | Morgan Stanley | Overweight |
모두보기
Cabaletta Bio Inc 주식(CABA)의 최신 뉴스
Cabaletta Bio, Inc. Set to Engage at Key Investor Conferences - MSN
Cabaletta Bio Unveils Promising Data on CABA-201 at ACR Convergence 2024 - MSN
Cabaletta Bio's SWOT analysis: CAR-T pioneer's stock faces pivotal moment - Investing.com
Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim’s Healthcare Innovation Conference! - MSN
Cabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial Advancements - MSN
Cabaletta Bio shares retain Buy rating as H.C. Wainwright sees robust treatment effect - Investing.com
Cabaletta reports promising autoimmune therapy results By Investing.com - Investing.com Australia
Cabaletta Bio Reports Q3 2024 Financial Results - TipRanks
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 - The Manila Times
Cabaletta reports promising autoimmune therapy results - Investing.com
Cabaletta Bio’s (CABA) Buy Rating Reiterated at HC Wainwright - Defense World
Inflammatory Myositis Treatment Market: Segmentation Trends, - openPR
Cabaletta Bio (NASDAQ:CABA) Given New $12.00 Price Target at Wells Fargo & Company - MarketBeat
Cabaletta Bio stock hits 52-week low at $3.47 amid market challenges - Investing.com UK
Cabaletta Bio's (CABA) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Cabaletta Bio Inc. (CABA) Quarterly 10-Q Report - Quartzy
T. Rowe Price Investment Management, Inc. Reduces Stake in Cabal - GuruFocus.com
Guggenheim maintains Buy on Cabaletta Bio with $23 target - Investing.com
Guggenheim maintains Buy on Cabaletta Bio with $23 target By Investing.com - Investing.com UK
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim's Healthcare Innovation Conference! - MyChesCo
Cabaletta Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference - The Manila Times
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference - Yahoo Finance
Vanguard Group Inc's Strategic Acquisition of Cabaletta Bio Inc Shares - GuruFocus.com
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
UBS Initiates Coverage of Cabaletta Bio (CABA) with Buy Recommendation - MSN
We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate - Yahoo Finance
Cabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Down 28.9% in October - MarketBeat
Undercovered Dozen: CorMedix, Cabaletta, Skyx Platforms, Dynex Capital + - Seeking Alpha
Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash - Seeking Alpha
State Street Corp's Strategic Reduction in Cabaletta Bio Inc Holdings - Yahoo Finance
State Street Corp's Strategic Reduction in Cabaletta Bio Inc Hol - GuruFocus.com
Short Interest in Cabaletta Bio, Inc. (NASDAQ:CABA) Drops By 16.7% - MarketBeat
Trading Day Review: Cabaletta Bio Inc (CABA) Gains Momentum, Closing at 4.21 - The Dwinnex
Millennium Management LLC Grows Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential - MSN
UBS sees significant upside for Cabaletta Bio despite recent share decline - Investing.com India
Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential (NASDAQ:KYTX) - Seeking Alpha
Healthy Upside Potential: Cabaletta Bio Inc (CABA) - SETE News
UBS sees significant upside for Cabaletta Bio despite recent share decline By Investing.com - Investing.com South Africa
Cabaletta Bio (NASDAQ:CABA) Now Covered by Analysts at UBS Group - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
A Guide To The Risks Of Investing In Cabaletta Bio Inc (CABA) - Knox Daily
Cabaletta Bio Inc (CABA) stock analysis: A comprehensive overview - US Post News
Cabaletta Bio Outlines Future Trials and Development Strategy - TipRanks
Squarepoint Ops LLC Has $2.36 Million Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Marshall Wace LLP Grows Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Get in on Cabaletta Bio Inc’s (CABA) buy-in window today! - SETE News
Should investors be concerned about Cabaletta Bio Inc (CABA)? - US Post News
Cabaletta Bio Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
Cabaletta Bio secures lease terms through August 2026 - Investing.com India
Cabaletta Bio Inc (CABA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):